Septerna, Inc. (SEPN) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGM. Market cap 1.72B USD. 52-week range 17.55 to 51.10 USD. Data as of 2026-10-09.
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; ...